Read more
This book demonstrates that the PPAR- Gamma agonist troglitazone (TRO) exhibited anti-inflammatory and anti-fibrotic properties in a murine model of BLEO-induced lung fibrosis and in vitro on human lung fibroblasts. As a preventive treatment for BLEO-induced lung fibrosis, TRO has demonstrated comparable abilities to reduce lung inflammatory cytokine levels, pulmonary recruitment of inflammatory cells and collagen deposition, loss of body weight and mortality rate. TRO demonstrated anti-fibrotic effects in reducing lung collagen/HYP levels during therapeutic treatment, whereas DEX was incapable of reducing these effects. TRO also exhibited anti-fibrotic properties in vitro by inhibiting TGF beta--induced -SMA protein expression and collagen secretion in lung fibroblast cultures. These results support the potential use of PPAR- Gamma agonists as therapeutic agents in the treatment of lung conditions characterised by inflammation and fibrosis.
About the author
Dr. Venkata Rami Reddy Narala is Associate Professor in Animal Science at Yogi Vemana University, Kadapa, Andhra Pradesh, India. His research interests are focused on the identification of ligands for nuclear receptors and study their role in airway inflammation and injury and recombinant DNA technology. He is the recipient of several awards.
